EUVIMEDEUVIMED entdecken
LeserbriefKommentar

The role of glycated haemoglobin in clinical decision‐making of diabetes overtreatment

Ilker Tasci iD

Diabetic Medicine · 2023-03 · 40 (3)

DOI: 10.1111/dme.15021 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Diabetic Medicine, online erschienen am 23.12.2022. Verfasst von Ilker Tasci. Beteiligte Einrichtung: Department of Internal Medicine, Gulhane Faculty of Medicine & Training and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Diabetes Mellitus, Type 1HumansGlycated HemoglobinClinical Decision-Making

Substanzen

Glycated Hemoglobin

Autor:innen und Institutionen

  • Department of Internal Medicine, Gulhane Faculty of Medicine & Training and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey.

ORCID-Profile: Ilker Tasci

Zitieren

APA

Tasci, I. (2023). The role of glycated haemoglobin in clinical decision‐making of diabetes overtreatment. Diabetic Medicine, 40(3). https://doi.org/10.1111/dme.15021

Vancouver

Tasci I. The role of glycated haemoglobin in clinical decision‐making of diabetes overtreatment. Diabetic Medicine. 2023;40(3). doi:10.1111/dme.15021

BibTeX
@article{Tasci2023,
  author = {Tasci, Ilker},
  title = {The role of glycated haemoglobin in clinical decision‐making of diabetes overtreatment},
  journal = {Diabetic Medicine},
  year = {2023},
  volume = {40},
  number = {3},
  doi = {10.1111/dme.15021}
}
Kostenlos starten →